The present invention relates compounds of Formula (A), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing certain neurological and psychiatric disorders and diseases as well as cancer in humans.

##STR00001##

Methods, filters and compositions are disclosed for treating toxicity due to oxidative stress and toxic electrophiles.

Methods, filters and compositions are disclosed for treating toxicity due to oxidative stress and toxic electrophiles.

Methods, filters and compositions are disclosed for treating toxicity due to oxidative stress and toxic electrophiles.

The present invention relates compounds of Formula (A), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing certain neurological and psychiatric disorders and diseases as well as cancer in humans. ##STR00001##

The present invention relates compounds of Formula (A), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing certain neurological and psychiatric disorders and diseases as well as cancer in humans. ##STR00001##

A method includes: (i) selecting a subject to which administration of an antipsychotic agent is desired; and (ii) administering a liquid formulation comprising the antipsychotic agent directly to cerebrospinal fluid (CSF)-containing space of the subject at a flow rate of less than 500 microliters per hour. The liquid formulation is administered for a period of time sufficient to reach a therapeutically effective steady state concentration in CSF of a brain of the subject.

A method includes: (i) selecting a subject to which administration of an antipsychotic agent is desired; and (ii) administering a liquid formulation comprising the antipsychotic agent directly to cerebrospinal fluid (CSF)-containing space of the subject at a flow rate of less than 500 microliters per hour. The liquid formulation is administered for a period of time sufficient to reach a therapeutically effective steady state concentration in CSF of a brain of the subject.

A novel dual neurotransmitter nanoparticle composition is provided to store and transport protons and cations into neural cell membranes and to disassemble salt-bridge stabilized toxic protein plaques. These properties function to mitigate cognitive deficits in neurological diseases such as Parkinson's disease and Alzheimer's disease, as well as to reduce the severity of aging related reactive oxygen species damage by the sequestration and termination of free radicals and reactive oxygen species. The composition comprises C60 bonded to one or more glutathione molecules and one or more molecules of either levodopa or dopamine. The composition can be produced at low temperatures through reactive shear milling. This composition therapeutically improves and prophylactically preserves cognitive performance, memory, and mental acuity on aging to promote mental performance and health-span improvement.

This invention relates to methods of administering compounds containing selenium, selenocysteine, or a selenocysteine peptide to treat, for example, conditions associated with selenium deficiency, or ferroptoptic, parthanototic, and endoplasmic reticulum stress, and/or cancer. The methods of treatment may activate or inhibit (via TFAP2C and Sp1 proteins) the adaptive homeostatic response of the selenome. The compounds may contain a targeting sequence that causes them to be delivered to specific organs and/or tissues. The compounds may be administered, for example, orally, intranasally, intravenously, or by a minimally invasive catheter or BrainPath.